Clinical Trials Logo

Hyperparathyroidism, Secondary clinical trials

View clinical trials related to Hyperparathyroidism, Secondary.

Filter by:

NCT ID: NCT00446329 Terminated - Clinical trials for Secondary Hyperparathyroidism

Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

Start date: July 2006
Phase: Phase 4
Study type: Interventional

The 1st phase of the study will assess the acute biochemical response of PTH, calcium and phosphorus to orally administered doses of cinacalcet once (60mg) or twice (30mg x 2) per day. The 2nd phase of the study designed to evaluate the long term effects of cinacalcet on BMD (bone mineral density)and the levels of PTH, calcium, phosphorus as well as its ability to control secondary hyperparathyroidism without simultaneous administration of other vitamin D compounds.

NCT ID: NCT00415584 Terminated - Clinical trials for Secondary Hyperparathyroidism

Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients

Start date: January 2007
Phase: Phase 1/Phase 2
Study type: Interventional

Secondary hyperparathyroidism can persist following successful renal transplantation and can cause high blood calcium, kidney dysfunction or failure and excessive bone loss among other problems. If the condition does not resolve, surgery is frequently required to remove the parathyroid glands, with all the inherent risks of surgery. Cinacalcet, a medicine used to treat secondary hyperparathyroidism in patients with kidney disease, may be effective in treating this condition in the renal transplant recipient. We will study the effect of cinacalcet on calcium, bone and renal function in a 6 month treatment protocol.

NCT ID: NCT00175149 Terminated - Clinical trials for Chronic Kidney Disease

Active Vitamin D Effect on Left Ventricular Hypertrophy

Start date: January 2002
Phase: Phase 4
Study type: Interventional

Left ventricular hypertrophy (LVH) predicts mortality at start of dialysis. Prevention of of LVH is important. It is not known whether secondary hyperparathyroidism might induce LVH. In the present study patients are randomised to 1.25 dihydroxycholecalciferol or no treatment to study the effect on LVH.